Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 26 results.
User Information
Export Records
  1. 1.   Synthesis and Biological Evaluation of Novel 2-Aroyl Benzofuran-Based Hydroxamic Acids as Antimicrotubule Agents
  2. Mariotto, Elena; Canton, Martina; Marchioro, Chiara; Brancale, Andrea; Hamel,Ernest; Varani, Katia; Vincenzi, Fabrizio; De Ventura, Tiziano; Padroni, Chiara; Viola, Giampietro; Romagnoli, Romeo
  3. International Journal of Molecular Sciences. 2024, Jul 09; 25(14):
  1. 2.   Synergistic TRAIL Sensitizers from Barleria alluaudii and Diospyros maritima
  2. Whitson, E. L.; Sun, H.; Thomas, C. L.; Henrich, C. J.; Sayers, T. J.; McMahon, J. B.; Griesinger, C.; McKee, T. C.
  3. Journal of Natural Products. 2012, Mar; 75(3): 394-399.
  1. 3.   Design and Synthesis of 2-Heterocyclyl-3-arylthio-1H-indoles as Potent Tubulin Polymerization and Cell Growth Inhibitors with Improved Metabolic Stability
  2. La Regina, G.; Bai, R.; Rensen, W.; Coluccia, A.; Piscitelli, F.; Gatti, V.; Bolognesi, A.; Lavecchia, A.; Granata, I.; Porta, A.; Maresca, B.; Soriani, A.; Iannitto, M. L.; Mariani, M.; Santoni, A.; Brancale, A.; Ferlini, C.; Dondio, G.; Varasi, M.; Mercurio, C.; Hamel, E.; Lavia, P.; Novellino, E.; Silvestri, R.
  3. Journal of Medicinal Chemistry. 2011, Dec; 54(24): 8394-8406.
  1. 4.   DNA intercalator korkormicin A preferentially kills tumor cells expressing wild type p53
  2. Kitagaki, J.; Yang, Y. L.
  3. Biochemical and Biophysical Research Communications. 2011, Oct; 414(1): 186-191.
  1. 5.   Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties
  2. Flynn, B. L.; Gill, G. S.; Grobelny, D. W.; Chaplin, J. H.; Paul, D.; Leske, A. F.; Lavranos, T. C.; Chalmers, D. K.; Charman, S. A.; Kostewicz, E.; Shackleford, D. M.; Morizzi, J.; Hamel, E.; Jung, M. K.; Kremmidiotis, G.
  3. Journal of Medicinal Chemistry. 2011, Sep; 54(17): 6014-6027.
  1. 6.   Antitumor Agents. 284. New Desmosdumotin B Analogues with Bicyclic B-Ring as Cytotoxic and Antitubulin Agents
  2. Nakagawa-Goto, K.; Wu, P. C.; Lai, C. Y.; Hamel, E.; Zhu, H.; Zhang, L. Y.; Kozaka, T.; Ohkoshi, E.; Goto, M.; Bastow, K. F.; Lee, K. H.
  3. Journal of Medicinal Chemistry. 2011, Mar; 54(5): 1244-1255.
  1. 7.   Synthesis and in vitro Evaluation of 3H-Pyrrolo[3,2-f]quinolin-9-one Derivatives That Show Potent and Selective Anti-leukemic Activity
  2. Ferlin, M. G.; Bortolozzi, R.; Brun, P.; Castagliuolo, I.; Hamel, E.; Basso, G.; Viola, G.
  3. Chemmedchem. 2010, Jul; 5(8): 1373-1385.
  1. 8.   Arsenic-Specific Stem Cell Selection During Malignant Transformation
  2. Tokar, E. J.; Qu, W.; Liu, J.; Liu, W.; Webber, M. M.; Phang, J. M.; Waalkes, M. P.
  3. Journal of the National Cancer Institute. 2010, May; 102(9): 638-649.
  1. 9.   Therapeutic agents from the sea: biodiversity, chemo-evolutionary insight and advances to the end of Darwin's 200th year
  2. Newman, D. J.; Cragg, G. M.; Battershill, C. N.
  3. Diving and Hyperbaric Medicine. 2009, Dec; 39(4): 216-225.
  1. 10.   Discovery of 8-methoxypyrazino[1,2-a]indole as a New Potent Antiproliferative Agent Against Human Leukemia K562 Cells. A Structure-Activity Relationship Study
  2. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Cruz-Lopez, O.; Cara, C. L.; Preti, D.; Tabrizi, M. A.; Balzarini, J.; Hamel, E.; Fabbri, E.; Gambari, R.
  3. Letters in Drug Design & Discovery. 2009 6(4): 298-303.
  1. 11.   Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
  2. Kitagaki, J.; Agama, K. K.; Pommier, Y.; Yang, Y. L.; Weissman, A. M.
  3. Molecular Cancer Therapeutics. 2008 7(8): 2445-2454.
  1. 12.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 13.   Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells
  2. Wallqvist, A.; Huang, R.; Covell, D. G.; Roschke, A. V.; Gelhaus, K. S.; Kirsch, I. R.
  3. Molecular Cancer Therapeutics. 2005, OCT; 4(10): 1559-1568.
  1. 14.   Structure-based discovery of a boronic acid bioisostere of combretastatin A-4
  2. Kong, Y.; Grembecka, J.; Edler, M. C.; Hamel, E.; Mooberry, S. L.; Sabat, M.; Rieger, J.; Brown, M. L.
  3. Chemistry & Biology. 2005, SEP; 12(9): 1007-1014.
  1. 15.   Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small-molecule screening and structural databases
  2. Covell, D. G.; Wallqvist, A.; Huang, R. L.; Thanki, N.; Rabow, A. A.; Lu, X. J.
  3. Proteins-Structure Function and Bioinformatics. 2005, MAY 15; 59(3): 403-433.
  1. 16.   The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase
  2. Marcus, A. I.; Zhou, J.; O'Brate, A.; Hamel, E.; Wong, J.; Nivens, N.; El-Naggar, A.; Yao, T. P.; Khuri, F. R.; Giannakakou, P.
  3. Cancer Research. 2005, MAY 1; 65(9): 3883-3893.
  1. 17.   Cytotoxicity of RH1: NAD(P)H : quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction
  2. Tudor, G.; Alley, M.; Nelson, C. M.; Huang, R. L.; Covell, D. G.; Gutierrez, P.; Sausville, E. A.
  3. Anti-Cancer Drugs. 2005 16(4): 381-391.
  1. 18.   Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel
  2. Svingen, P. A.; Loegering, D.; Rodriquez, J.; Meng, X. W.; Mesner, P. W.; Holbeck, S.; Monks, A.; Krajewski, S.; Scudiero, D. A.; Sausville, E. A.; Reed, J. C.; Lazebnik, Y. A.; Kaufmann, S. H.
  3. Clinical Cancer Research. 2004, OCT 15; 10(20): 6807-6820.
  1. 19.   Analytical challenges faced in designing potential anticancer agents from nitric oxide (NO)-releasing diazeniumdiolate prodrugs
  2. Waterhouse, D. J.; Saavedra, J. E.; Citro, M. L.; Buzard, G. S.; Ji, X. H.; Xu, X.; Fox, S. D.; Veenstra, T. D.; Keefer, L. K.
  3. Abstracts of Papers of the American Chemical Society. 2004, MAR 28; 227(081-ANYL, Part 1): U91-U91.
  1. 20.   Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XLAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
  2. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z. J.; Tomita, Y.; Li, P.; Roller, P. P.; Wang, R. X.; Fang, X. L.; Guo, R. B.; Zhang, M. C.; Lippman, M. E.; Yang, D. J.; Wang, S. M.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2430-2440.
  1. 21.   Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression
  2. Tudor, G.; Gutierrez, P.; Aguilera-Gutierrez, A.; Sausville, E. A.
  3. Biochemical Pharmacology. 2003 65(7): 1061-1075.
  1. 22.   Marine pharmacology in 2000: Antitumor and cytotoxic compounds
  2. Mayer, A. M. S.; Gustafson, K. R.
  3. International Journal of Cancer. 2003 105(3): 291-299.
  1. 23.   Medicinals for the millennia - The historical record
  2. Cragg, G. M.; Newman, D. J.
  3. New Vistas in Therapeutics, from Drug Design to Gene Therapy: Drug-Resistant Tuberculosis, from Molecules to Macro-Economics. 2001; 953 : 3-25.
  1. 24.   A new anti-tubulin agent containing the benzo
  2. Pinney, K. G.; Bounds, A. D.; Dingeman, K. M.; Mocharla, V. P.; Pettit, G. R.; Bai, R.; Hamel, E.
  3. Bioorganic & Medicinal Chemistry Letters. 1999 9(8): 1081-1086.
  1. 25.   Analysis of Brefeldin a and the Prodrug Breflate in Plasma By Gas Chromatography With Mass Selective Detection
  2. Phillips, L. R.; Wolfe, T. L.; Malspeis, L.; Supko, J. G.
  3. Journal of Pharmaceutical and Biomedical Analysis. 1998 16(8): 1301-1309.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel